p90 RSK2 Mediates Antianoikis Signals by both Transcription-Dependent and-Independent Mechanisms

Molecular and Cellular Biology

Volumn 33, Issue 13, 2013, Pages 2574-2585

  Jin, Lingtao ^a   Li, Dan ^a   Lee, Jong Seok ^a   Elf, Shannon ^a   Alesi, Gina N ^a   Fan, Jun ^a   Kang, Hee Bum ^a   Wang, Dongsheng ^a   Fu, Haian ^a   Taunton, Jack ^b   Boggon, Titus J ^c   Tucker, Meghan ^d   Gu, Ting Lei ^d   Chen, Zhuo G ^a   Shin, Dong M ^a   Khuri, Fadlo R ^a   Kang, Sumin ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d CELL SIGNALING TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOPTOSIS SIGNAL REGULATING KINASE 1; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE KINASE 6; PROAPOPTOTIC FACTOR INHIBITOR OF GROWTH PROTEIN 3; PROTEIN SERINE THREONINE KINASE; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE 6; SERINE THREONINE KINASE RSK2; UNCLASSIFIED DRUG;

ANOIKIS; ARTICLE; CANCER CELL; CELL INVASION; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN CELL; METASTASIS; PRIORITY JOURNAL;

ADENOSINE TRIPHOSPHATE; ANOIKIS; CELL LINE, TUMOR; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; GENE EXPRESSION REGULATION; GENES, TUMOR SUPPRESSOR; HOMEODOMAIN PROTEINS; HUMANS; MAP KINASE KINASE 6; MAP KINASE KINASE KINASE 5; NEOPLASM PROTEINS; PHOSPHORYLATION; PROTEIN-TYROSINE KINASES; RIBOSOMAL PROTEIN S6 KINASES, 90-KDA; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC;

EID: 84880648928     PISSN: 02707306     EISSN: 10985549     Source Type: Journal    
DOI: 10.1128/MCB.01677-12     Document Type: Article

References (37)

1. Gupta GP, Massague J. 2006. Cancer metastasis: building a framework. Cell 127:679-695.
2. Fidler IJ. 2003. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat. Rev. Cancer 3:453-458.
3. Kang S, Elf S, Lythgoe K, Hitosugi T, Taunton J, Zhou W, Xiong L, Wang D, Muller S, Fan S, Sun SY, Marcus AI, Gu TL, Polakiewicz RD, Chen GZ, Khuri FR, Shin DM, Chen J. 2010. p90 ribosomal S6 kinase 2 promotes invasion and metastasis of human head and neck squamous cell carcinoma cells. J. Clin. Invest. 120:1165-1177.
4. Blenis J. 1993. Signal transduction via the MAP kinases: proceed at your own RSK. Proc. Natl. Acad. Sci. U. S. A. 90:5889-5892.
5. Frodin M, Gammeltoft S. 1999. Role and regulation of 90 kDa ribosomal S6 kinase (RSK) in signal transduction. Mol. Cell. Endocrinol. 151:65-77.
6. Fisher TL, Blenis J. 1996. Evidence for two catalytically active kinase domains in pp90rsk. Mol. Cell. Biol. 16:1212-1219.
7. Buck M, Poli V, Hunter T, Chojkier M. 2001. C/EBPbeta phosphorylation by RSK creates a functional XEXD caspase inhibitory box critical for cell survival. Mol. Cell 8:807-816.
8. He Z, Ma WY, Liu G, Zhang Y, Bode AM, Dong Z. 2003. Arsenite-induced phosphorylation of histone H3 at serine 10 is mediated by Akt1, extracellular signal-regulated kinase 2, and p90 ribosomal S6 kinase 2 but not mitogen- and stress-activated protein kinase 1. J. Biol. Chem. 278: 10588-10593.
9. Palmer A, Gavin AC, Nebreda AR. 1998. A link between MAP kinase and p34(cdc2)/cyclin B during oocyte maturation: p90(rsk) phosphorylates and inactivates the p34(cdc2) inhibitory kinase Myt1. EMBO J. 17:5037-5047.
10. Shimamura A, Ballif BA, Richards SA, Blenis J. 2000. Rsk1 mediates a MEK-MAP kinase cell survival signal. Curr. Biol. 10:127-135.
11. Dehan E, Bassermann F, Guardavaccaro D, Vasiliver-Shamis G, Cohen M, Lowes KN, Dustin M, Huang DC, Taunton J, Pagano M. 2009. betaTrCP- and Rsk1/2-mediated degradation of BimEL inhibits apopto-sis. Mol. Cell 33:109-116.
12. Wu D, Zhau HE, Huang WC, Iqbal S, Habib FK, Sartor O, Cvitanovic L, Marshall FF, Xu Z, Chung LW. 2007. cAMP-responsive element-binding protein regulates vascular endothelial growth factor expression: implication in human prostate cancer bone metastasis. Oncogene 26: 5070-5077.
13. Jean D, Bar-Eli M. 2000. Regulation of tumor growth and metastasis of human melanoma by the CREB transcription factor family. Mol. Cell. Biochem. 212:19-28.
14. Jean D, Tellez C, Huang S, Davis DW, Bruns CJ, McConkey DJ, Hinrichs SH, Bar-Eli M. 2000. Inhibition of tumor growth and metastasis of human melanoma by intracellular anti-ATF-1 single chain Fv fragment. Oncogene 19:2721-2730.
15. Jean D, Harbison M, McConkey DJ, Ronai Z, Bar-Eli M. 1998. CREB and its associated proteins act as survival factors for human melanoma cells. J. Biol. Chem. 273:24884-24890.
16. Xie S, Price JE, Luca M, Jean D, Ronai Z, Bar-Eli M. 1997. Dominant-negative CREB inhibits tumor growth and metastasis of human melanoma cells. Oncogene 15:2069-2075.
17. Xing J, Ginty DD, Greenberg ME. 1996. Coupling of the RAS-MAPK pathway to gene activation by RSK2, a growth factor-regulated CREB kinase. Science 273:959-963.
18. Kim AH, Khursigara G, Sun X, Franke TF, Chao MV. 2001. Akt phosphorylates and negatively regulates apoptosis signal-regulating kinase 1. Mol. Cell. Biol. 21:893-901.
19. Zhang R, Luo D, Miao R, Bai L, Ge Q, Sessa WC, Min W. 2005. Hsp90-Akt phosphorylates ASK1 and inhibits ASK1-mediated apoptosis. Oncogene 24:3954-3963.
20. Gu JJ, Wang Z, Reeves R, Magnuson NS. 2009. PIM1 phosphorylates and negatively regulates ASK1-mediated apoptosis. Oncogene 28:4261-4271.
21. Cohen MS, Zhang C, Shokat KM, Taunton J. 2005. Structural bioinformatics-based design of selective, irreversible kinase inhibitors. Science 308:1318-1321.
22. Kang S, Dong S, Gu TL, Guo A, Cohen MS, Lonial S, Khoury HJ, Fabbro D, Gilliland DG, Bergsagel PL, Taunton J, Polakiewicz RD, Chen J. 2007. FGFR3 activates RSK2 to mediate hematopoietic transformation through tyrosine phosphorylation of RSK2 and activation of the MEK/ERK pathway. Cancer Cell 12:201-214.
23. Kang S, Dong S, Guo A, Ruan H, Lonial S, Khoury HJ, Gu TL, Chen J. 2008. Epidermal growth factor stimulates RSK2 activation through activation of the MEK/ERK pathway and Src-dependent tyrosine phosphor-ylation of RSK2 at Tyr-529. J. Biol. Chem. 283:4652-4657.
24. Kang S, Elf S, Dong S, Hitosugi T, Lythgoe K, Guo A, Ruan H, Lonial S, Khoury HJ, Williams IR, Lee BH, Roesel JL, Karsenty G, Hanauer A, Taunton J, Boggon TJ, Gu TL, Chen J. 2009. Fibroblast growth factor receptor 3 associates with and tyrosine phosphorylates p90 RSK2, leading to RSK2 activation that mediates hematopoietic transformation. Mol. Cell. Biol. 29:2105-2117.
25. Hitosugi T, Fan J, Chung TW, Lythgoe K, Wang X, Xie J, Ge Q, Gu TL, Polakiewicz RD, Roesel JL, Chen GZ, Boggon TJ, Lonial S, Fu H, Khuri FR, Kang S, Chen J. 2011. Tyrosine phosphorylation of mitochondrial pyruvate dehydrogenase kinase 1 is important for cancer metabolism. Mol. Cell 44:864-877.
26. Li C, Wong WH. 2001. Model-based analysis of oligonucleotide arrays: expression index computation and outlier detection. Proc. Natl. Acad. Sci. U.S.A. 98:31-36.
27. Smith JA, Poteet-Smith CE, Xu Y, Errington TM, Hecht SM, Lannigan DA. 2005. Identification of the first specific inhibitor of p90 ribosomal S6 kinase (RSK) reveals an unexpected role for RSK in cancer cell proliferation. Cancer Res. 65:1027-1034.
28. Aubele M, Vidojkovic S, Braselmann H, Ritterswurden D, Auer G, Atkinson MJ, Tapio S, Hofler H, Rauser S, Bartlett JM. 2009. Overexpression of PTK6 (breast tumor kinase) protein-a prognostic factor for long-term breast cancer survival-is not due to gene amplification. Vir-chows Arch. 455:117-123.
29. Xiang B, Chatti K, Qiu H, Lakshmi B, Krasnitz A, Hicks J, Yu M, Miller WT, Muthuswamy SK. 2008. Brk is coamplified with ErbB2 to promote proliferation in breast cancer. Proc. Natl. Acad. Sci. U. S. A. 105:12463-12468.
30. Schmandt RE, Bennett M, Clifford S, Thornton A, Jiang F, Broaddus RR, Sun CC, Lu KH, Sood AK, Gershenson DM. 2006. The BRK tyrosine kinase is expressed in high-grade serous carcinoma of the ovary. Cancer Biol. Ther. 5:1136-1141.
31. Irie HY, Shrestha Y, Selfors LM, Frye F, Iida N, Wang Z, Zou L, Yao J, Lu Y, Epstein CB, Natesan S, Richardson AL, Polyak K, Mills GB, Hahn WC, Brugge JS. 2010. PTK6 regulates IGF-1-induced anchorage-independent survival. PLoS One 5:e11729. doi:10.1371/journal.pone.0011729.
32. Ythier D, Larrieu D, Brambilla C, Brambilla E, Pedeux R. 2008. The new tumor suppressor genes ING: genomic structure and status in cancer. Int. J. Cancer 123:1483-1490.
33. Campos EI, Chin MY, Kuo WH, Li G. 2004. Biological functions of the ING family tumor suppressors. Cell. Mol. Life Sci. 61:2597-2613.
34. Gunduz M, Ouchida M, Fukushima K, Ito S, Jitsumori Y, Nakashima T, Nagai N, Nishizaki K, Shimizu K. 2002. Allelic loss and reduced expression of the ING3, a candidate tumor suppressor gene at 7q31, in human head and neck cancers. Oncogene 21:4462-4470.
35. Richards HW, Medrano EE. 2009. Epigenetic marks in melanoma. Pigment Cell Melanoma Res. 22:14-29.
36. Wang Y, Dai DL, Martinka M, Li G. 2007. Prognostic significance of nuclear ING3 expression in human cutaneous melanoma. Clin. Cancer Res. 13:4111-4116.
37. Wang Y, Li G. 2006. ING3 promotes UV-induced apoptosis via Fas/caspase-8 pathway in melanoma cells. J. Biol. Chem. 281:11887-11893.